Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application

Protalix BioTherapeutics Inc PLX has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April.
The FDA issued the response letter for pegunigalsidase alfa (PRX-102) in Fabry disease, though no reasons were cited in the letter.
The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.
Price Action: PLX shares are up 4.63% at $1.58 during the premarket session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.